Stable and efficient Paclitaxel nanoparticles for targeted glioblastoma therapy

Advanced Healthcare Materials
Qingxin MuMiqin Zhang

Abstract

Development of efficient nanoparticles (NPs) for cancer therapy remains a challenge. NPs are required to have high stability, uniform size, sufficient drug loading, targeting capability, and ability to overcome drug resistance. In this study, the development of a NP formulation that can meet all these challenging requirements for targeted glioblastoma multiform (GBM) therapy is reported. This multifunctional NP is composed of a polyethylene glycol-coated magnetic iron oxide NP conjugated with cyclodextrin and chlorotoxin (CTX) and loaded with fluorescein and paclitaxel (PTX) (IONP-PTX-CTX-FL). The physicochemical properties of the IONP-PTX-CTX-FL are characterized by transmission electron microscope, dynamic light scattering, and high-performance liquid chromatography. The cellular uptake of NPs is studied using flow cytometry and confocal microscopy. Cell viability and apoptosis are assessed with the Alamar Blue viability assay and flow cytometry, respectively. The IONP-PTX-CTX-FL had a uniform size of ≈44 nm and high stability in cell culture medium. Importantly, the presence of CTX on NPs enhanced the uptake of the NPs by GBM cells and improved the efficacy of PTX in killing both GBM and GBM drug-resistant cells. The IONP-PT...Continue Reading

References

Jan 1, 1989·AJR. American Journal of Roentgenology·R WeisslederJ Lewis
Jan 1, 1994·International Journal of Clinical & Laboratory Research·R FoaA D Seidman
Feb 1, 1993·The American Journal of Physiology·J A DeBinG R Strichartz
Feb 24, 2001·Journal of Pharmaceutical and Biomedical Analysis·H KimA A Nomeir
Nov 28, 2002·The Journal of Biological Chemistry·Jessy DeshaneHarald Sontheimer
Feb 7, 2003·Current Cancer Drug Targets·R Z YusufM V Seiden
Jun 10, 2005·Nano Letters·Omid VeisehMiqin Zhang
Jan 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael S BobolaJohn R Silber
Aug 2, 2008·The New England Journal of Medicine·Patrick Y Wen, Santosh Kesari
Nov 17, 2009·Advanced Drug Delivery Reviews·Omid VeisehMiqin Zhang
Dec 19, 2009·The Journal of Biological Chemistry·Kamala KesavanDouglas B Jacoby
Apr 14, 2010·Pharmaceutical Research·Rameshwar PatilJulia Y Ljubimova
May 3, 2011·Accounts of Chemical Research·Forrest M Kievit, Miqin Zhang
Jan 26, 2012·Pharmaceutical Research·Mehmet V YigitZdravka Medarova

❮ Previous
Next ❯

Citations

Oct 6, 2015·Advanced Materials·Wei CuiGero Decher
Feb 7, 2017·Chemistry : a European Journal·Tina SkorjancAli Trabolsi
Nov 15, 2018·Journal of Translational Internal Medicine·Justin S MichaelJohn S Yu
Mar 12, 2020·Nanomaterials·Mohammad NorouziDonald W Miller
Jan 28, 2020·Journal of Chemotherapy·Vahid RezaeiFarzaneh Khademi
Sep 21, 2019·Future Medicinal Chemistry·Ming-Hsien LinJia-You Fang
Jul 19, 2019·Daru : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences·Soodeh SalarpourAbbas Pardakhty
Jan 1, 2021·Advances in Colloid and Interface Science·Sergio Gómez-GrañaPablo Hervés
Mar 7, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Shalini Sundramurthi ChelliahIshwar Parhar
Mar 20, 2021·Frontiers in Cell and Developmental Biology·Hang SongJinghui Wang
May 15, 2021·Biotechnology Advances·Julien GiribaldiChristina I Schroeder

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis